Adamas Pharmaceuticals (ADMS) Getting Somewhat Favorable News Coverage, Study Finds

News stories about Adamas Pharmaceuticals (NASDAQ:ADMS) have trended somewhat positive on Friday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.2118983552535 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Shares of Adamas Pharmaceuticals (NASDAQ ADMS) opened at $37.39 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35. Adamas Pharmaceuticals has a 52 week low of $13.50 and a 52 week high of $38.75. The stock has a market cap of $851.70, a P/E ratio of -11.13 and a beta of 1.13.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.03). Adamas Pharmaceuticals’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.66) EPS. sell-side analysts predict that Adamas Pharmaceuticals will post -3.84 EPS for the current year.

Several equities analysts recently commented on ADMS shares. Evercore ISI started coverage on shares of Adamas Pharmaceuticals in a research report on Monday, October 30th. They set an “outperform” rating for the company. Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Northland Securities started coverage on shares of Adamas Pharmaceuticals in a research report on Wednesday, November 29th. They set an “outperform” rating for the company. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Adamas Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $44.86.

COPYRIGHT VIOLATION NOTICE: “Adamas Pharmaceuticals (ADMS) Getting Somewhat Favorable News Coverage, Study Finds” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2018/01/19/adamas-pharmaceuticals-adms-given-news-impact-score-of-0-10.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply